Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: To assess the long-term benefit-risk profile of repeated courses of rituximab in Caucasian patients affected by neuromyelitis optica (NMO) and related disorders, in everyday clinical practice. Methods: This is a prospective observational study performed at San Raffaele Hospital, Milan, Italy. From February 2006, we recruited 21 patients affected by NMO and NMO spectrum of disorders (NMOSD) whom underwent at least one cycle of intravenous (i.v.) rituximab and then were followed for at least 2 years. Results: At a mean follow-up time of 48 months, we observed a significant reduction of the annualized relapse rate (ARR), from 2.0 to 0.16 ( p < 0.01); and of the median Expanded Disability Status Scale (EDSS), from 5.5 to 4.0 ( p < 0.013). There were 12 patients (57%) who remained disease free during the follow-up period. Five patients (24%) reported mild hematological adverse events. Serious infectious adverse events were reported by another four patients: These were all wheelchair bound at the beginning of their rituximab treatment. Conclusions: A fixed treatment scheme of rituximab, with re-treatment every 6 months, was efficacious for NMO and NMOSD, with a good safety profile; however, to obtain an even better benefit-risk ratio, close monitoring of CD19 + B cells should be performed before the re-treatment of patients with high-level disability, concomitant leukopenia and hypogammaglobulinemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Kitley, J., Leite, M. I., Nakashima, I., Waters, P., McNeillis, B., Brown, R., Takai, Y., Takahashi, T., Misu, T., Elsone, L., et al. (2012) · Brain · doi:10.1093/brain/aws109 · Cited by 438
Pathogenic T cell responses against aquaporin 4
Pohl, M., Fischer, M.-T., Mader, S., Schanda, K., Kitic, M., Sharma, R., Wimmer, I., Misu, T., Fujihara, K., Reindl, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0824-0 · Cited by 98
Cited by
Damato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00888 · Cited by 227
Neuromyelitis optica and neuromyelitis optica spectrum disorders
Marignier, R., Cobo Calvo, A., & Vukusic, S. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000455 · Cited by 45
Deletional tolerance prevents AQP4‐directed autoimmunity in mice
Vogel, A., Knier, B., Lammens, K., Kalluri, S. R., Kuhlmann, T., Bennett, J. L., & Korn, T. (2017) · European Journal of Immunology · doi:10.1002/eji.201646855 · Cited by 34
Metadata
- Authors
- Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V, Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V, & Comi, G.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2015-07-21
- Volume
- 22
- Issue
- 4
- Pages
- 511-519
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2242473891
- Cited by
- 85
- References
- 3
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. https://app.cochat.ai/papers/10.1177/1352458515594042
- The paper
- Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V, Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V, & Comi, G. (2016). Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458515594042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.